Öz
Objectives: To evaluate the efficacy of topical clobetasol
propionate 0.05% pomade in the treatment of idiopathic
granulomatous mastitis.
Patients and Methods: Twenty-one idiopathic granulomatous
mastitis patients’ clinical and histopathological findings were
retrospectively reviewed. Those patients excluded from other
etiologies were categorized as idiopathic granulomatous mastitis
and treated with topical clobetasol propionate 0.05% pomade as
an initial treatment.
Results: All 21 patients with a final diagnosis of idiopathic
granulomatous mastitis were women with the average age of
36.2+/-5.2 years. Of the 21 patients; erythema, induration and pain
problems of 6 (28.5%) patients totally resolved without recurrence
in 3 months follow-up period. Erythema, induration and pain
problems of 7 (33.5%) patients were minimalized and stay stable
in 3 months follow-up period. The symptoms of 8 (38%) did not
change under topical clobetasol propionate treatment. None of the
patients developed side or adverse effects due to topical steroid
treatment and 6 of 18 patients with non-steroidal anti-inflammatory
drugs (NSAIDs) complained of gastric pain.
Conclusion:Topical steroid treatment is a safe treatment option
for idiopathic granulomatous mastitis patients before systemic
steroid and immunosuppressive treatments and also surgery.